Overview
Brainsway makes brainwashing a good thing. The company developed the Deep TMS (transcranial magnetic stimulation) system, a helmet-shaped medical device that transmits magnetic pulses to stimulate deep brain regions. The Deep TMS system is designed to treat neurological and psychopathological disorders such as Alzheimer's disease, bipolar disorder, depression, Parkinson's disease, post-traumatic stress disorder, and schizophrenia. The device is
...
Read More intended for patients who don't respond to pharmaceuticals; a treatment session lasts about 20 minutes and takes at least four weeks. The Deep TMS system has been approved for use in the European Union and Israel; clinical trials are still being conducted in the US.
Read Less
Read More intended for patients who don't respond to pharmaceuticals; a treatment session lasts about 20 minutes and takes at least four weeks. The Deep TMS system has been approved for use in the European Union and Israel; clinical trials are still being conducted in the US.
Read Less
HADAR LEVI
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Medical research, commercial
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
$31.78 million
Actual
29.04%
$94
DEC
?
?
Tel Aviv:BWAY
Contacts
Get in Touch with 9 Principals*
-
HADAR LEVIChief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2023 (12 month period) in USD
Annual Revenue 2024
$31.78 million
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $10 | $1 | -$10 |
| Net Investing Cash | $30 | -$37 | $42 |
| Net Financing Cash | $18 | -$1 | -$2 |
| Net Change in Cash | $59 | -$37 | $31 |
| Cash at Beginning of Period | $11 | $48 | $17 |
| Cash at End of Period | $69 | $11 | $48 |
| Capital Expenditure | -$4 | -$2 | $ |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $69 | $11 | $48 |
| Accounts Receivable | $5 | $4 | $5 |
| Inventories | $4 | $4 | $4 |
| Other Current Assets | $1 | $37 | $2 |
| Asset Summary | |||
| Total Current Assets | $80 | $55 | $58 |
| Tangible Fixed Assets | $12 | $6 | $5 |
| Intangible Assets | $ | $ | $ |
| Total Assets | $94 | $63 | $64 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $3 | $1 | $1 |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $12 | $9 | $7 |
| Liability Summary | |||
| Total Current Liabilities | $15 | $10 | $8 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $ | $ | $6 |
| Total Liabilities | $32 | $21 | $19 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $0 | $0 | $0 |
| Retained Earnings | -$98 | -$101 | -$97 |
| Equity Summary | |||
| Total Equity | $62 | $42 | $45 |
| Shares Outstanding | 37,626,427 | 33,242,189 | 33,053,323 |